Google DeepMind: Revealing the Structure of apoB100 Protein
Researchers from the University of Missouri (Mizzou) have successfully mapped the structure of apoB100, a large protein that forms the molecular scaffold of low-density lipoprotein (LDL), commonly known as "bad cholesterol." This breakthrough, powered by Google DeepMind's AlphaFold, provides a detailed atomic-resolution model of a protein that has defied mapping for 50 years.
The Role of apoB100 in Cardiovascular Disease
Low-density lipoprotein (LDL) is the primary carrier of fat through the bloodstream and is a critical risk factor for atherosclerotic cardiovascular disease (ASCVD), which is the world's leading cause of death. The apoB100 protein is the essential structural component that gives LDL its form. Understanding the precise structure of this protein is necessary to understand how bad cholesterol becomes harmful in the body and to develop more effective prevention and treatment strategies for ASCVD.
Technical Approach: Combining AI and Microscopy
Mapping apoB100 was historically difficult because of the protein's immense size and its complex interactions with fats and other molecules. To overcome these challenges, researchers Zachary Berndsen and Keith Cassidy used a hybrid approach:
- Cryo-electron microscopy (cryo-EM): Used to capture initial images of LDL particles. While these images lacked the atomic precision required for a full map, they provided the necessary experimental framework.
- AlphaFold: Used to generate atomic-resolution predictions of the protein's structure.
By refining the AlphaFold predictions against the cryo-EM image data, the team was able to interpret the experimental structure with atomic precision.
Key Structural Discoveries
The resulting model reveals that apoB100 acts as a cage-like shell that wraps around each LDL particle. A key discovery within this structure is a ribbon-like belt that serves to keep the LDL particle intact while it circulates in the bloodstream.
Implications for Future Medicine
Revealing the structure of apoB100 provides a foundation for new diagnostic and therapeutic interventions. By knowing the exact shape and arrangement of the protein, scientists can now explore therapies that target LDL more precisely, potentially transforming the clinical approach to treating high cholesterol and atherosclerotic cardiovascular disease.